VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/23/15 -- Response Biomedical Corp. ("Response") (TSX: RBM)(OTCQB: RPBIF) will release its first quarter 2015 financial results before the markets open on Tuesday May 5, 2015.
Additionally, Response announces that Dr. Barb Kinnaird, Chief Operating Officer and Mr. Bill Adams, Chief Financial Officer, will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 5, 2015 at 3:30 p.m. EDT in the Mackenzie Room of the Sheraton Centre Toronto Hotel, Toronto, Ontario.
Response's Annual General Meeting will be held on Tuesday, May 19, 2015 at 11:00 a.m. PDT at the Company's corporate office, 1781 -75th Avenue W, Vancouver, BC.
About Response Biomedical Corp.
Response develops, manufactures and markets rapid onsite diagnostic tests for use with its RAMP® platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and nonmedical immunoassay based test currently performed in laboratories. Response's clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, thromboembolism and infectious diseases. In the nonclinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus antigen and for Biodefense applications including the rapid onsite detection of anthrax, smallpox, ricin and botulinum toxin. Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTCQB under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.
Contacts:
Response Biomedical Corp.
W.J. (Bill) Adams
Chief Financial Officer
604-456-6010
ir@responsebio.com
www.responsebio.com
